Scientists have discovered that proteins found in the blood of rattlesnakes can effectively neutralize venom from multiple dangerous snake species. In laboratory experiments, combinations of these proteins were found to be about 10 times more effective than existing commercial antivenoms, which are typically made from the blood of animals like sheep. This discovery, led by Sean B. Carroll, a Distinguished University Professor of Biology at the University of Maryland, was published in the Proceedings of the National Academy of Sciences. The findings suggest the possibility of developing more effective, nature-inspired treatments for snakebites. The study focused on proteins called FETUA-3, which are naturally present in rattlesnake blood. These proteins can block the activity of metalloproteinases, a group of toxins found in western diamondback rattlesnake venom that cause damage by breaking down tissues and causing excessive bleeding. However, no single FETUA protein was enough to completely prevent death from a venomous bite. When combined, the proteins worked together more effectively, offering broader protection against the harmful effects of venom than any single protein alone. Researchers, including Elda Sánchez from Texas A&M University-Kingsville, studied how each FETUA protein contributed to venom resistance. They found that while individual proteins could counteract specific venom effects, such as reducing bleeding or stopping enzymes from causing damage, combinations of these proteins offered more comprehensive protection. Optimized mixtures of these proteins were not only more potent but also completely neutralized the lethal effects of rattlesnake venom, providing protection against multiple species of vipers. The study focused specifically on metalloproteinases, but the research team is now applying the same strategy to other types of venom toxins. Sean B. Carroll noted that these findings could lead to the development of recombinant antivenoms inspired by nature. Such treatments could first be used in veterinary medicine and eventually in human healthcare. The research was supported by the Howard Hughes Medical Institute and the Viper Resource Center.